Video: An overview of the monkeypox virus

Video: An overview of the monkeypox virus

Kalpana Pot walks us through the latest information on the monkeypox outbreak.

Leaps.org

Click below for an overview of everything you need to know about the latest status of monkeypox - in 58 seconds.



An Overview of Monkeypox with Kalpana Pot

An Overview of the Monkeypox Virus youtube.com

Kalpana Pot
Kalpana Pot is the youngest of three girls in a family full of doctors. Science and education were always of great value in her home. But performing arts was another passion for her, which is why she moved to LA to pursue acting after decades of dancing and singing. She’s appeared on numerous TV shows and national commercials, and will soon be co-hosting Wheel of Fortune Live. At the same time, Kalpana got to express her nerd love of astronomy by working weekends at Griffith Observatory. It was there that she found her love and skill in communicating science to people from all over the world, and has since continued to host space/science series. She has translated that onto digital platforms as well- running an outspoken space-page on TikTok, called TokNerdyToMe, and style and science page on Instagram. Unfortunately, much of her science communication these days is about debunking anti-science conspiracies. But she’s confident that the rise of educational content on social media will help this unfortunate problem in society. Outside of work, Kalpana loves her dogs and volunteers for animal organizations.
Can AI chatbots help with eating disorders?

A chatbot from the nonprofit National Eating Disorders Association aimed to provide 24/7 guidance on eating disorders. Several drawbacks point to the importance of therapist-tech collaboration in multiple areas of health.

Adobe Stock

Her name was Tessa and she was there to help. That’s what Sharon Maxwell read, anyway. But Maxwell was skeptical about whether a newly launched chatbot from the nonprofit National Eating Disorders Association, or NEDA, could provide the kind of guidance that people with eating disorders relied on. Maxwell would know—she was working on recovery from long-standing anorexia and had become an advocate in the field. So Maxwell took a deep breath and asked, “Hi Tessa. How do you support folks with eating disorders?”

Tessa’s reply was immediate. “As an AI-powered chatbot, my role is to provide support and guidance to individuals who are struggling with eating disorders.”

So far, so good. Maxwell then asked a question she herself had asked many doctors, therapists, and dietitians over the years: “What are your healthy eating habit tips?” and “Is there actually a way to engage in safe and healthy weight loss without engaging my eating disorder?”

Keep Reading Keep Reading
Carrie Arnold
Carrie Arnold is an independent public health journalist from Virginia.
Questions remain about new drug for hot flashes

In May, a new drug, Fezolinetant, was approved by the FDA to treat hot flashes associated with menopause.

Adobe Stock

Vascomotor symptoms (VMS) is the medical term for hot flashes associated with menopause. You are going to hear a lot more about it because a company has a new drug to sell. Here is what you need to know.

Menopause marks the end of a woman’s reproductive capacity. Normal hormonal production associated with that monthly cycle becomes erratic and finally ceases. For some women the transition can be relatively brief with only modest symptoms, while for others the body's “thermostat” in the brain is disrupted and they experience hot flashes and other symptoms that can disrupt daily activity. Lifestyle modification and drugs such as hormone therapy can provide some relief, but women at risk for cancer are advised not to use them and other women choose not to do so.

Fezolinetant, sold by Astellas Pharma Inc. under the product name Veozah™, was approved by the Food and Drug Administration (FDA) on May 12 to treat hot flashes associated with menopause. It is the first in a new class of drugs called neurokinin 3 receptor antagonists, which block specific neurons in the brain “thermostat” that trigger VMS. It does not appear to affect other symptoms of menopause. As with many drugs targeting a brain cell receptor, it must be taken continuously for a few days to build up a good therapeutic response, rather than working as a rescue product such as an asthma inhaler to immediately treat that condition.

Keep Reading Keep Reading
Bob Roehr
Bob Roehr is a biomedical journalist based in Washington, DC. Over the last twenty-five years he has written extensively for The BMJ, Scientific American, PNAS, Proto, and myriad other publications. He is primarily interested in HIV, infectious disease, immunology, and how growing knowledge of the microbiome is changing our understanding of health and disease. He is working on a book about the ways the body can at least partially control HIV and how that has influenced (or not) the search for a treatment and cure.